Equity Overview
Price & Market Data
Price: $2.01
Daily Change: -$0.08 / 3.98%
Daily Range: $2.01 - $2.10
Market Cap: $148,301,216
Daily Volume: 481,761
Performance Metrics
1 Week: -7.37%
1 Month: 11.05%
3 Months: 7.49%
6 Months: -15.90%
1 Year: -64.80%
YTD: -19.28%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country:
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.